<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836458</url>
  </required_header>
  <id_info>
    <org_study_id>CKAE609A2201</org_study_id>
    <nct_id>NCT01836458</nct_id>
  </id_info>
  <brief_title>A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection</brief_title>
  <official_title>An Open-label Study to Find the Minimum Inhibitory Concentration(MIC) of KAE609 in Adult Male Patients With Acute, Uncomplicated Malaria Due to Plasmodium Falciparum Monoinfection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male
      patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single
      dosing with KAE609
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a total of approximately 45 patients recruited into this study and six doses of
      KAE609 and will be investigated.The dose groups will run in sequence. Patient will be given a
      single dose of KAE609 and be followed up for 42 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimum Inhibitory Concentration (MIC) of KAE609</measure>
    <time_frame>Up to Day 8 after a single dose of KAE609</time_frame>
    <description>To observe the exposure-response (PK/PD) relationship for a single dose of KAE609. The key parameter is MIC, defined as the concentration at which the relative rate of change in parasitemia is equal to zero. Approximation of MIC will assist in identifying the optimal dose of KAE609, which will be one component of a future combination antimalarial. MIC could not be determined due to small sample size no data was collected from any participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Parasite Clearance</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 54, 60, 66, 72 hours post dose of KAE609</time_frame>
    <description>Parasite clearance time will be estimated using thick/thin blood films.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Fever Clearance</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>Fever is monitored on participants every 4 hours for the first 24 hours, then every 6 hours until negative reading obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 &amp; Day 42</measure>
    <time_frame>Day 28, Day 35 &amp; Day 42</time_frame>
    <description>PCR-corrected cure rate after a single dose of KAE609 by Day 28, Day 35 &amp; Day 42. PCR-corrected cure rate accounts for failures due to reappearance of parasites that were present in the blood before treatment (i.e. recrudescent infection) but not for failures due to a post-treatment inoculation (i.e. new infection).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Dose 1: 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of KAE609 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2: 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of KAE609 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3: 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of KAE609 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4: 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of KAE609 15 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAE609</intervention_name>
    <description>Patients will receive KAE609 single dose at a different dose level in each cohort.</description>
    <arm_group_label>Dose 1: 30 mg</arm_group_label>
    <arm_group_label>Dose 2: 20 mg</arm_group_label>
    <arm_group_label>Dose 3: 10 mg</arm_group_label>
    <arm_group_label>Dose 4: 15 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Monoinfection with P. falciparum confirmed by microscopy

          -  Asexual P. falciparum parasitemia count of 5,000 to 50,000/µL

          -  Axillary temperature ≥37.5 ºC or oral/tympanic/rectal temperature ≥38 ºC; or similar
             documented temperature during the previous 24 hours

          -  Body weight between 40 to 90 kg

        Key Exclusion Criteria:

          -  Signs and symptoms of severe malaria according to World Health Organization (WHO) 2010
             criteria

          -  Mixed Plasmodium infection, i.e. infection with more than one species of malaria
             parasites

          -  Use of other investigational drugs within 30 days or within 5 half-lives of
             enrollment, whichever is longer

          -  History of antimalarial use within 2 months of screening

          -  Use of any antibiotics with antimalarial activity or other prohibited medication
             within 14 days of screening

          -  Long QT syndrome or QTc using Fridericia's formula &gt;430 msec

          -  History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years, regardless of whether
             there is evidence of local recurrence or metastases

          -  Hemoglobin level &lt;10 g/dL

          -  Liver disease or injury as indicated by elevated liver tests such as SGPT (ALT) or
             SGOT (AST) &gt;2 times the upper limit of normal

          -  Renal dysfunction as indicated by serum creatinine &gt;2 times the upper limit of normal
             in the absence of dehydration; in case of dehydration, serum creatinine should be &lt;2
             times the upper limit of normal after oral or parental rehydration

          -  Known to be immunocompromised (including HIV infection) or are receiving
             immunosuppressive therapy at the time or enrollment; HIV testing is not required

          -  Known history of hepatitis B or C; testing is not required

          -  Febrile condition due to diseases other than malaria (e.g. acute lower respiratory
             tract infection), known underlying chronic or severe disease (e.g. cardiac, hepatic,
             renal, gastrointestinal, neurologic, or psychiatric disease), or any condition
             precluding enrollment into this study according to the investigator

          -  Severe vomiting defined as &gt;3 times during the previous 24 hours or inability to
             tolerate oral medication; severe diarrhea defined as ≥3 watery stools during the
             previous 24 hours

          -  Severe malnutrition defined by a body mass index (BMI) &lt;18.5 kg/m2 or unintentional
             loss of weight ≥10% with evidence of suboptimal intake resulting in loss of
             subcutaneous fat and/or severe muscle wasting

          -  Active tuberculosis or history of taking anti-tuberculosis medications within 24
             months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <results_first_submitted>March 8, 2016</results_first_submitted>
  <results_first_submitted_qc>September 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2016</results_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria, KAE609</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose 1: 30 mg</title>
          <description>Single dose of KAE609 30 mg</description>
        </group>
        <group group_id="P2">
          <title>Dose 2: 20 mg</title>
          <description>Single dose of KAE609 20 mg</description>
        </group>
        <group group_id="P3">
          <title>Dose 3: 10 mg</title>
          <description>Single dose of KAE609 10 mg</description>
        </group>
        <group group_id="P4">
          <title>Dose 4: 15 mg</title>
          <description>Single dose of KAE609 15 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose 1: 30 mg</title>
          <description>Single dose of KAE609 30 mg</description>
        </group>
        <group group_id="B2">
          <title>Dose 2: 20 mg</title>
          <description>Single dose of KAE609 20 mg</description>
        </group>
        <group group_id="B3">
          <title>Dose 3: 10 mg</title>
          <description>Single dose of KAE609 10 mg</description>
        </group>
        <group group_id="B4">
          <title>Dose 4: 15 mg</title>
          <description>Single dose of KAE609 15 mg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="11.84"/>
                    <measurement group_id="B2" value="32.8" spread="7.93"/>
                    <measurement group_id="B3" value="30.6" spread="8.24"/>
                    <measurement group_id="B4" value="34.7" spread="8.79"/>
                    <measurement group_id="B5" value="32.7" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>MALE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Minimum Inhibitory Concentration (MIC) of KAE609</title>
        <description>To observe the exposure-response (PK/PD) relationship for a single dose of KAE609. The key parameter is MIC, defined as the concentration at which the relative rate of change in parasitemia is equal to zero. Approximation of MIC will assist in identifying the optimal dose of KAE609, which will be one component of a future combination antimalarial. MIC could not be determined due to small sample size no data was collected from any participants.</description>
        <time_frame>Up to Day 8 after a single dose of KAE609</time_frame>
        <population>The primary Outcome Measure (OM) could not be determined due to small sample size no data was collected from any participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose 1: 30 mg</title>
            <description>Single dose of KAE609 30 mg</description>
          </group>
          <group group_id="O2">
            <title>Dose 2: 20 mg</title>
            <description>Single dose of KAE609 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Dose 3: 10 mg</title>
            <description>Single dose of KAE609 10 mg</description>
          </group>
          <group group_id="O4">
            <title>Dose 4: 15 mg</title>
            <description>Single dose of KAE609 15 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Inhibitory Concentration (MIC) of KAE609</title>
          <description>To observe the exposure-response (PK/PD) relationship for a single dose of KAE609. The key parameter is MIC, defined as the concentration at which the relative rate of change in parasitemia is equal to zero. Approximation of MIC will assist in identifying the optimal dose of KAE609, which will be one component of a future combination antimalarial. MIC could not be determined due to small sample size no data was collected from any participants.</description>
          <population>The primary Outcome Measure (OM) could not be determined due to small sample size no data was collected from any participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Parasite Clearance</title>
        <description>Parasite clearance time will be estimated using thick/thin blood films.</description>
        <time_frame>pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 54, 60, 66, 72 hours post dose of KAE609</time_frame>
        <population>Pharmacodynamic Analysis Set includes all enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dose 1: 30 mg</title>
            <description>Single dose of KAE609 30 mg</description>
          </group>
          <group group_id="O2">
            <title>Dose 2: 20 mg</title>
            <description>Single dose of KAE609 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Dose 3: 10 mg</title>
            <description>Single dose of KAE609 10 mg</description>
          </group>
          <group group_id="O4">
            <title>Dose 4: 15 mg</title>
            <description>Single dose of KAE609 15 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Parasite Clearance</title>
          <description>Parasite clearance time will be estimated using thick/thin blood films.</description>
          <population>Pharmacodynamic Analysis Set includes all enrolled patients</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" lower_limit="12.00" upper_limit="48.00"/>
                    <measurement group_id="O2" value="63.00" lower_limit="36.02" upper_limit="72.00"/>
                    <measurement group_id="O3" value="54.00" lower_limit="36.05">Only 4 of 7 patients reached time to parasite clearance; therefore, it was not possible to calculate the upper limit of the 95% confidence interval.</measurement>
                    <measurement group_id="O4" value="60.00" lower_limit="36.00" upper_limit="72.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Fever Clearance</title>
        <description>Fever is monitored on participants every 4 hours for the first 24 hours, then every 6 hours until negative reading obtained.</description>
        <time_frame>Day 1 to Day 5</time_frame>
        <population>Pharmacodynamic Analysis Set includes all enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dose 1: 30 mg</title>
            <description>Single dose of KAE609 30 mg</description>
          </group>
          <group group_id="O2">
            <title>Dose 2: 20 mg</title>
            <description>Single dose of KAE609 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Dose 3: 10 mg</title>
            <description>Single dose of KAE609 10 mg</description>
          </group>
          <group group_id="O4">
            <title>Dose 4: 15 mg</title>
            <description>Single dose of KAE609 15 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Fever Clearance</title>
          <description>Fever is monitored on participants every 4 hours for the first 24 hours, then every 6 hours until negative reading obtained.</description>
          <population>Pharmacodynamic Analysis Set includes all enrolled patients</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.83" lower_limit="0.83" upper_limit="11.92"/>
                    <measurement group_id="O2" value="12.38" lower_limit="3.83" upper_limit="29.83"/>
                    <measurement group_id="O3" value="15.75" lower_limit="0.75" upper_limit="15.83"/>
                    <measurement group_id="O4" value="11.83" lower_limit="4.83" upper_limit="35.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 &amp; Day 42</title>
        <description>PCR-corrected cure rate after a single dose of KAE609 by Day 28, Day 35 &amp; Day 42. PCR-corrected cure rate accounts for failures due to reappearance of parasites that were present in the blood before treatment (i.e. recrudescent infection) but not for failures due to a post-treatment inoculation (i.e. new infection).</description>
        <time_frame>Day 28, Day 35 &amp; Day 42</time_frame>
        <population>Pharmacodynamic Analysis Set includes all enrolled patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose 1: 30 mg</title>
            <description>Single dose of KAE609 30 mg</description>
          </group>
          <group group_id="O2">
            <title>Dose 2: 20 mg</title>
            <description>Single dose of KAE609 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Dose 3: 10 mg</title>
            <description>Single dose of KAE609 10 mg</description>
          </group>
          <group group_id="O4">
            <title>Dose 4: 15 mg</title>
            <description>Single dose of KAE609 15 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 &amp; Day 42</title>
          <description>PCR-corrected cure rate after a single dose of KAE609 by Day 28, Day 35 &amp; Day 42. PCR-corrected cure rate accounts for failures due to reappearance of parasites that were present in the blood before treatment (i.e. recrudescent infection) but not for failures due to a post-treatment inoculation (i.e. new infection).</description>
          <population>Pharmacodynamic Analysis Set includes all enrolled patients.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dose 1: 30mg</title>
          <description>Single dose of KAE609 30 mg</description>
        </group>
        <group group_id="E2">
          <title>Dose 2: 20mg</title>
          <description>Single dose of KAE609 20 mg</description>
        </group>
        <group group_id="E3">
          <title>Dose 3: 10mg</title>
          <description>Single dose of KAE609 10 mg</description>
        </group>
        <group group_id="E4">
          <title>Dose 4: 15mg</title>
          <description>Single dose of KAE609 15 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

